Mammographic density in relation to breast cancer recurrence and survival in women receiving neoadjuvant chemotherapy
(2023) In Frontiers in Oncology 13.- Abstract
Objective: The association between mammographic density (MD) and breast cancer (BC) recurrence and survival remains unclear. Patients receiving neoadjuvant chemotherapy (NACT) are in a vulnerable situation with the tumor within the breast during treatment. This study evaluated the association between MD and recurrence/survival in BC patients treated with NACT. Methods: Patients with BC treated with NACT in Sweden (2005–2016) were retrospectively included (N=302). Associations between MD (Breast Imaging-Reporting and Data System (BI-RADS) 5th Edition) and recurrence-free/BC-specific survival at follow-up (Q1 2022) were addressed. Hazard ratios (HRs) for recurrence/BC-specific survival (BI-RADS a/b/c vs. d) were estimated using... (More)
Objective: The association between mammographic density (MD) and breast cancer (BC) recurrence and survival remains unclear. Patients receiving neoadjuvant chemotherapy (NACT) are in a vulnerable situation with the tumor within the breast during treatment. This study evaluated the association between MD and recurrence/survival in BC patients treated with NACT. Methods: Patients with BC treated with NACT in Sweden (2005–2016) were retrospectively included (N=302). Associations between MD (Breast Imaging-Reporting and Data System (BI-RADS) 5th Edition) and recurrence-free/BC-specific survival at follow-up (Q1 2022) were addressed. Hazard ratios (HRs) for recurrence/BC-specific survival (BI-RADS a/b/c vs. d) were estimated using Cox regression analysis and adjusted for age, estrogen receptor status, human epidermal growth factor receptor 2 status, axillary lymph node status, tumor size, and complete pathological response. Results: A total of 86 recurrences and 64 deaths were recorded. The adjusted models showed that patients with BI-RADS d vs. BI-RADS a/b/c had an increased risk of recurrence (HR 1.96 (95% confidence interval (CI) 0.98–3.92)) and an increased risk of BC-specific death (HR 2.94 (95% CI 1.43–6.06)). Conclusion: These findings raise questions regarding personalized follow-up for BC patients with extremely dense breasts (BI-RADS d) pre-NACT. More extensive studies are required to confirm our findings.
(Less)
- author
- Zdanowski, Anna ; Sartor, Hanna LU ; Feldt, Maria LU and Skarping, Ida LU
- organization
-
- Radiology Diagnostics, Malmö (research group)
- LUCC: Lund University Cancer Centre
- Department of Translational Medicine
- Breast cancer prevention & intervention (research group)
- Breastcancer
- Tumor microenvironment
- Breastcancer-genetics
- Breast cancer treatment
- The Liquid Biopsy and Tumor Progression in Breast Cancer (research group)
- publishing date
- 2023-06-14
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- breast cancer neoadjuvant therapy, breast density, imaging, mammographic density (MD), survival analysis (MeSH NLM)
- in
- Frontiers in Oncology
- volume
- 13
- article number
- 1177310
- publisher
- Frontiers Media S. A.
- external identifiers
-
- pmid:37388229
- scopus:85163719516
- ISSN
- 2234-943X
- DOI
- 10.3389/fonc.2023.1177310
- language
- English
- LU publication?
- yes
- id
- 19a693db-d6dc-47a6-973c-309a12fd3c66
- date added to LUP
- 2023-10-10 13:54:31
- date last changed
- 2024-04-19 02:11:33
@article{19a693db-d6dc-47a6-973c-309a12fd3c66, abstract = {{<p>Objective: The association between mammographic density (MD) and breast cancer (BC) recurrence and survival remains unclear. Patients receiving neoadjuvant chemotherapy (NACT) are in a vulnerable situation with the tumor within the breast during treatment. This study evaluated the association between MD and recurrence/survival in BC patients treated with NACT. Methods: Patients with BC treated with NACT in Sweden (2005–2016) were retrospectively included (N=302). Associations between MD (Breast Imaging-Reporting and Data System (BI-RADS) 5<sup>th</sup> Edition) and recurrence-free/BC-specific survival at follow-up (Q1 2022) were addressed. Hazard ratios (HRs) for recurrence/BC-specific survival (BI-RADS a/b/c vs. d) were estimated using Cox regression analysis and adjusted for age, estrogen receptor status, human epidermal growth factor receptor 2 status, axillary lymph node status, tumor size, and complete pathological response. Results: A total of 86 recurrences and 64 deaths were recorded. The adjusted models showed that patients with BI-RADS d vs. BI-RADS a/b/c had an increased risk of recurrence (HR 1.96 (95% confidence interval (CI) 0.98–3.92)) and an increased risk of BC-specific death (HR 2.94 (95% CI 1.43–6.06)). Conclusion: These findings raise questions regarding personalized follow-up for BC patients with extremely dense breasts (BI-RADS d) pre-NACT. More extensive studies are required to confirm our findings.</p>}}, author = {{Zdanowski, Anna and Sartor, Hanna and Feldt, Maria and Skarping, Ida}}, issn = {{2234-943X}}, keywords = {{breast cancer neoadjuvant therapy; breast density; imaging; mammographic density (MD); survival analysis (MeSH NLM)}}, language = {{eng}}, month = {{06}}, publisher = {{Frontiers Media S. A.}}, series = {{Frontiers in Oncology}}, title = {{Mammographic density in relation to breast cancer recurrence and survival in women receiving neoadjuvant chemotherapy}}, url = {{http://dx.doi.org/10.3389/fonc.2023.1177310}}, doi = {{10.3389/fonc.2023.1177310}}, volume = {{13}}, year = {{2023}}, }